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Background: Patients with type-2 diabetes mellitus (T2DM) and hypertension have increased risk of cardiovascular
disease (CVD). We studied individualized treatment targets and their achievement in clinical practice.
Methods: DIALOGUE is a prospective, multi-center registry in patients with both T2DM and hypertension.
Results: Patients (n = 6,586) had a baseline fasting glucose (8.5 ± 2.8 mmol/l), postprandial glucose (10.9 ± 3.4 mmol/l),
and HbA1c (7.8 ± 2.1%) levels indicated poor glycemic control. Baseline systolic and diastolic BP were 140.3 ± 15.7 and
82.6 ± 9.5, respectively. Patients were categorized by HbA1c treatment goals: ≤6.5% (strict), >6.5 to ≤7.0% (medium),
and >7.0 to ≤7.5% (loose). When considering systolic BP (SBP) targets (≤130 mmHg [strict], >130 to ≤135 mmHg
[medium], and >135 to ≤140 mmHg [loose]), patients with strict SBP treatment goals displayed similar characteristics to
those with strict HbA1c targets. Although approximately 70% of patients received both strict HbA1c and SBP targeting,
overall treatment goals remained unmet in all HbA1c target groups at the 6-month follow-up. SBP targets were not
reached in the strict and medium groups, but were achieved in the loose treatment group. Specific predictors for
choosing loose SBP or HbA1c treatment goals were identified, including SBP/HbA1c levels and various comorbidities.
Conclusions: Individualized glucose and BP targets were selected by treating physicians based on patient
characteristics and overall comorbidity. While treatment goals were not consistently met using various antidiabetic and
antihypertensive therapies, our analyses indicated that the strictly targeted patient populations maintained lower
overall HbA1c and SBP levels at 6 months.Background
A large body of evidence indicates that type-2 diabetes
mellitus (T2DM) is an important independent risk factor
for cardiovascular disease (CVD). In fact, those with dia-
betes are 2 to 4 times more likely to develop CVD,
which is the leading cause of mortality in patients with
T2DM [1]. In addition, the prevalence of hypertension is
more than double in diabetic patients compared to those
with normal blood glucose levels [1], making it the most
common comorbid disease associated with T2DM [2].* Correspondence: roland.schmieder@uk-erlangen.de
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unless otherwise stated.Hypertension has been found to increase the risk of ne-
phropathy, retinopathy, left ventricular hypertrophy, and
cardiovascular events in patients with T2DM [1].
Current guidelines have recommended a multi-factorial
approach for treating diabetic patients with hypertension,
involving simultaneous targeting of blood pressure (BP)
and glucose levels [3]. Although there has been a recent
focus on individualized treatment targets in patients with
T2DM [4], guidelines have not been sufficiently translated
into clinical practice [5]. Moreover, adequate guidance
with regard to individualized BP targets remains to be
established [6,7]. Thus, in order to define effective criteria
for individualized treatment approaches, information re-
garding patient characteristics that might be associatedtral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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gation into the efficacy of meeting individualized thera-
peutic goals set by physicians in daily clinical practice are
fundamental. This is especially important considering that
drugs that perform well within specialized populations in
clinical trials are often less effective when employed in clin-
ical practice. Thus, it is also essential to carefully evaluate
whether treatment targets can be met using specific antidia-
betic and antihypertensive therapies in unselected patient
populations and within real clinical settings. For this reason,
comparisons between different drug classes are required.
The ongoing DIALOGUE registry represents the first
study to assess the effectiveness, tolerability, and impact
of different therapeutic approaches in patients with
T2DM and hypertension while applying newly estab-
lished individualized treatment targets recommended by
the American Diabetes Association (ADA) and the Euro-
pean Association for the Study of Diabetes (EASD) [4].
Here, we aimed to characterize patients based on their
chosen therapeutic targets as well as actual target
achievement rates (overall and by comorbidity). Further-
more, we identified patient characteristics associated
with loose treatment goals.
Methods
Study design
DIALOGUE is an ongoing, prospective, observational,
non‐interventional, multi-center disease registry with a
follow-up of up to 24 months (i.e., 6, 12 and 24 months)
in Germany. Diabetologists and primary care physicians
are in charge of continued patient enrollment at selected
centers, which were chosen from a database (Stiftung
Institut für Herzinfarktforschung) to be representative of
ambulatory care for diabetes and hypertension. This
registry is being conducted in accordance with the Dec-
laration of Helsinki and adheres to the principles of
Good Epidemiology Practice. Moreover this investigation
has followed applicable regulatory requirements, and the
study protocol was approved by the ethics committee of
the Ruhr University (Bochum, Germany). In addition, all
patients provided written informed consent, and DIA-
LOGUE was registered in the database of the Verband
forschender Arzneimittelhersteller (http://www.vfa.de/
de/arzneimittel-forschung/datenbanken-zu-arzneimit-
teln/nisdb). The study protocol, as well as primary
and secondary objectives of DIALOGUE, have been
previously published in detail [8]. Decisions regarding
individual therapies and treatment goals (HbA1c and
BP) were made solely by the attending physician based
on their clinical assessment.
Patients
Patients were consecutively enrolled based on the follow-
ing criteria: at least 18 years old; T2DM and manifestedcomorbid hypertension; current use of oral mono‐ or dual
combination antidiabetic therapy; treating physician con-
sidered blood glucose lowering medication as inadequate
and/or not safe/tolerable; the physician added an add-
itional oral drug or switched drug treatment to achieve
glycemic control (excluding glucagon-like peptide [GLP-1]
analogues and insulin). Patients were not eligible for inclu-
sion if any of the following criteria applied: current partici-
pation in a randomized controlled trial; not under regular
supervision of the treating physician during the study; use
of GLP-1 analogues or insulin before enrollment; treated
with aliskiren in a dual renin-angiotensin-aldosterone sys-
tem (RAAS) blockade; pregnancy; diabetes secondary to
malnutrition, infection or surgery; maturity onset diabetes
of the young; and known cancer.
Data collection and quality assurance
Data were recorded using a web-based electronic case re-
port form (eCRF). Among other information, the follow-
ing information was collected: patient characteristics
(basic characteristics, medical history, and comorbidities);
medical therapy for secondary prevention of cardio‐vascu-
lar complications; glucose profile (fasting glucose, post‐
prandial glucose, HbA1c); BP; and body mass index
(BMI). Office BP was assessed with standard oscillometric
devices available at the physician’s office with a calibration
validation. Data quality was ensured upon eCRF entry,
prior to creation of the analysis data set, and through on-
site monitoring (2% of the sites randomly selected).
Statistical analyses
Continuous variables were summarized using standard sta-
tistics (i.e., mean, standard deviation, minimum, median,
maximum, lower and upper quartile), whereas percentages
were calculated for categorical data. Comparisons between
treatment groups were performed using Pearson´s chi-
squared test for categorical variables and the Kruskal–
Wallis test for continuous measures. Predictors for tar-
get group selection were identified through multivariate
analysis. All statistical analyses were performed using
SAS (release 9.2 or higher; Cary, NC, USA). P-values ≤ 0.05
were considered to be significant.
Results
Recruitment for DIALOGUE began in July 2012, with
8,632 patients documented as of May 2014. Here, we
present baseline data for these patients and analyze data
from those completing the 6-month follow-up (n = 6,586).
Baseline patient characteristics
The characteristics of the study participants are pre-
sented in Table 1. Patients displayed a median age of
65 years, and less than a quarter were > 75 years old. Ap-
proximately half of the patients were female. There was
Table 1 Baseline patient characteristics for all subjects and each HbA1c target group




HbA1c > 6.5% to ≤ 7.0%
(n = 3,644)
HbA1c > 7.0% to ≤ 7.5%
(n = 1,618)
P-values for the
comparison of 3 groups
Age (years) 65.0 (57.0-74.0) 64.0 (55.0-73.0) 67.0 (59.0-74.0) 66.0 (58.0-75.0) <0.0001
Age > 75 years (%) 19.7 17.7 20.5 22.0 <0.001
Female sex (%) 45.6 46.2 45.5 44.4 0.47
BMI (kg/m2) 31.2 ± 5.9 31.1 ± 5.9 31.3 ± 5.8 31.4 ± 6.0 0.38
BMI > 30 kg/m2 (%) 52.0 51.3 52.1 53.1 0.47
Waist circumference (cm) 107.6 ± 14.5 107.0 ± 15.0 108.0 ± 14.0 108.0 ± 14.7 0.50
Current smokers (%) 11.8 11.4 12.0 11.9 0.73
Diabetes duration (months) 67.9 (31.7-117.3) 55.7 (24.8-100.6) 75.1 (35.7-122.4) 82.7 (40.4-131.8) <0.0001
Fasting glucose (mmol/l) 8.5 ± 2.8 7.8 ± 2.6 8.8 ± 2.6 9.7 ± 3.1 <0.0001
Postprandial glucose (mmol/l) 10.9 ± 3.4 10.0 ± 3.2 11.2 ± 3.3 12.1 ± 3.7 <0.0001
HbA1c (%) 7.8 ± 2.1 7.2 ± 1.3 8.0 ± 2.8 8.6 ± 1.5 <0.0001
≤6.5% (%) 14.7 28.9 7.1 2.0 <0.0001
>6.5% to≤ 7.0% (%) 17.4 25.6 16.2 2.5 <0.0001
>7.0% to≤ 7.5% (%) 19.8 17.7 23.1 16.8 <0.0001
SBP (mmHg) 140.3 ± 15.7 139.5 ± 15.9 140.7 ± 15.5 141.3 ± 15.6 <0.0001
DBP (mmHg) 82.6 ± 9.5 82.4 ± 9.8 82.7 ± 9.2 83.0 ± 9.4 <0.01
HR (beats/min) 75.0 ± 10.0 74.7 ± 10.4 75.0 ± 9.4 75.9 ± 10.5 <0.0001
Legend: HbA1c, glycated hemoglobin; body mass index, BMI; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; *for one patient no HbA1c
target was indicated; data are provided as medians (interquartile range), percent or mean ± standard deviation.
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tenth were recorded as current smokers. Mean diabetes
duration was approximately 6 years. Baseline fasting and
postprandial glucose measurements, as well as HbA1c
levels, indicated poor glycemic control in our cohort (as
expected by study design). Finally, mean BP was found to
be 140 ± 15.7/83 ± 9.5 (systolic/diastolic), and the average
heart rate was within normal range.
Individualized treatment targets
Patients were categorized into three groups based on ini-
tial HbA1c treatment goals: ≤6.5% (strict group), >6.5 to
≤7.0% (medium), and >7.0 to ≤7.5% (loose) (Table 1).
The loose treatment group contained approximately half
as many patients as the other two groups. Patients in the
strict target group were younger and displayed a shorter
disease duration compared to the other treatment
groups (p < 0.0001). In addition, they presented lower
fasting/postprandial blood glucose and HbA1c values
(all p < 0.0001). Moreover, patients with strict HbA1c
goals displayed significantly lower BP and heart rate as
well as significantly less comorbid disease at baseline
than the other groups (Figure 1, upper panel).
Similarly, patients were also divided based on target sys-
tolic BP (SBP: ≤130 mmHg [strict], >130 to ≤135 mmHg
[medium], and >135 to ≤140 mmHg [loose]) (Table 2).
When considering patients within the SBP target groups,
we found that those with strict treatment goals were
significantly younger and had a shorter diabetes duration(p < 0.0001). Also, they displayed better glycemic control
(p < 0.0001), lower BP measurements (p < 0.0001), and sig-
nificantly less co-morbid disease when compared to the
other SBP target groups (Figure 1, lower panel).
Therefore, our data indicated that key similarities
existed between patients within the strict HbA1c and
SBP target groups. Thus, we further analyzed the rela-
tionship between patients with distinct HbA1c and SBP
treatment goals. Strikingly, we found that approximately
70% of the patients who received strict HbA1c targeting
also had strict SBP treatment goals (Figure 2). Moreover,
cross comparison of patients within the medium and
loose treatment groups revealed similar results, with
52% and 60% of patients in the respective HbA1c target
groups fitting within the corresponding SBP treatment
groups.
In particular, factors contributing to the assignment
of patients into the loose target groups for SBP and
HbA1c were of interest. With this respect, multivariate
analysis revealed several adjusted predictors for select-
ing loose treatment goals (Table 3). We found that
loose SBP targets were weakly correlated with age, fast-
ing blood glucose (FBG), heart failure, peripheral artery
disease (PAD), and absence of non-proliferative diabetic
retinopathy (NPDR); SBP at baseline was the strongest
predictor. On the other hand, loose HbA1c targets
could be weakly correlated with longer diabetes duration,














































































































Figure 1 Comorbidities according to HbA1c (upper panel) and BP (lower panel) target groups. Legend: HbA1c, glycated hemoglobin; SBP, systolic
blood pressure; TIA, transient ischemic attack; PAD, peripheral arterial disease; NPDR, non-proliferative diabetic retinopathy.
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group
We also analyzed therapeutic patterns in the HbA1c and
SBP target groups, observing significant differences with
regard to specific antidiabetic and antihypertensive ther-
apies (Table 4). The lowest use of various antidiabetictherapies occurred in the strict HbA1c target group. In
addition, this group was administered the lowest drug
doses (data not shown). In contrast, the medium HbA1c
target group showed significantly higher amounts of use
of metformin, alpha-glucosidase, and dipeptidyl peptidase-
4 (DDP-4) inhibitors, whereas those patients with loose
Table 2 Baseline patient characteristics by SBP target group
Baseline characteristic All subjects
(n = 8,632*)
SBP ≤ 130 mmHg
(n = 3,342)
SBP > 130
to ≤ 135 mmHg
(n = 2,870)
SBP > 135





Age (years) 65.0 (57.0-74.0) 64.0 (55.0-72.0) 66.0 (58.0-74.0) 68.0 (59.0-75.0) <0.0001
Age > 75 years (%) 19.7 16.7 20.5 22.8 <0.0001
Female sex (%) 45.6 46.1 44.8 45.5 0.59
BMI (kg/m2) 31.2 ± 5.9 31.1 ± 5.8 31.2 ± 5.7 31.4 ± 6.1 0.48
BMI > 30 kg/m2 (%) 52.0 51.4 51.8 52.9 0.53
Waist circumference (cm) 107.6 ± 14.5 107.8 ± 15.1 107.4 ± 13.7 107.5 ± 14.8 0.68
Current smokers (%) 11.8 12.1 11.5 11.6 0.77
Diabetes duration (months) 67.9 (31.7-117.3) 61.4 (27.6-109.7) 71.2 (34.1-120.2) 72.7 (34.1-121.1) <0.0001
Fasting glucose (mmol/l) 8.5 ± 2.8 8.2 ± 2.7 8.7 ± 2.8 8.8 ± 2.9 <0.0001
Postprandial glucose (mmol/l) 10.9 ± 3.4 10.5 ± 3.2 11.2 ± 3.4 11.1 ± 3.6 <0.0001
HbA1c (%) 7.8 ± 2.1 7.5 ± 1.4 7.9 ± 1.4 8.1 ± 3.4 <0.0001
SBP (mmHg) 140.3 ± 15.7 136.4 ± 15.5 140.7 ± 14.8 145.2 ± 15.4 <0.0001
≤ 130 mmHg (%) 32.0 45.2 28.1 17.8 <0.0001
> 130 to≤ 135 mmHg (%) 9.2 8.8 12.4 5.8 <0.0001
> 135 to≤ 140 mmHg (%) 21.7 18.2 22.4 26.1 <0.0001
DBP (mmHg) 82.6 ± 9.5 81.3 ± 9.5 82.9 ± 9.1 84.1 ± 9.7 <0.0001
HR (beats/min) 75.0 ± 10.0 74.5 ± 10.0 75.2 ± 10.2 75.6 ± 10.2 <0.0001
Legend: SBP, systolic blood pressure; BMI, body mass index; HbA1c, glycated hemoglobin; DBP, diastolic blood pressure; HR, heart rate; *for 36 patients no SBP
target was indicated; data are provided as medians (interquartile range), percent or mean ± standard deviation.
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ureas and insulin (short-acting, long-acting, and mixed)
(p < 0.0001). With regard to antihypertensive therapies,
there were fewer significant differences observed between
the distinct SBP target groups. However, we found that
the loose target group was more often prescribed ACE in-





















































Figure 2 Proportion of patients with the indicated SBP goals within each Hb
hemoglobin. *P < 0.0001 for all comparisons between HbA1c target groups.corresponding to the higher prevalence of comorbidities
in this group.
Six-month follow-up by HbA1c or SBP target group
At the 6-month follow-up (n = 6,586), we found that pa-
tients within the strict HbA1c treatment group had made
more contacts with general practitioners (p < 0.0001,SBP  130 mmHg
SBP  135 mmHg
SBP  140 mmHg
A1c  6.5%
A1c target group. Legend: SBP, systolic blood pressure; HbA1c, glycated
Table 3 Multivariable adjusted predictors for choosing a loose treatment target
SBP > 135 to ≤ 140 mmHg HbA1c >7.0% to ≤ 7.5%
uni (OR; 95%CI) multi (OR; 95%CI) uni (OR; 95%CI) multi (OR; 95%CI)
Age (years) (≥ vs. < median) 1.37 (1.24-1.51) 1.28 (1.04-1.56) 1.11 (1.00-1.24) 0.95 (0.74-1.21)
Female sex (%) 1.00 (0.91-1.10) 1.01 (0.84-1.22) 0.94 (0.85-1.05) 1.22 (0.97-1.54)
BMI (kg/m2) (≥ vs. < median) 1.06 (0.96-1.16) 1.07 (0.86-1.34) 1.09 (0.98-1.22) 0.94 (0.72-1.23)
Waist circumference (cm) (≥ vs. < median) 1.08 (0.91-1.27) 1.01 (0.81-1.26) 1.05 (0.87-1.28) 1.00 (0.77-1.31)
Current smokers (%) 0.98 (0.84-1.14) 1.13 (0.85-1.50) 1.02 (0.86-1.21) 1.15 (0.82-1.61)
Diabetes duration (months) (≥ vs. < median) 1.14 (1.03-1.26) 0.97 (0.80-1.17) 1.50 (1.34-1.67) 1.36 (1.09-1.70)
FBG (mmol/l) (≥ vs. < median) 1.38 (1.24-1.53) 1.29 (1.06-1.58) 2.31 (2.03-2.62) 1.24 (0.96-1.59)
HbA1c (%)(≥ vs. < median) 1.33 (1.20-1.47) 1.14 (0.93-1.41) 4.03 (3.58-4.53) 3.20 (2.47-4.05)
SBP (mmHg) (≥ vs. < median) 2.83 (2.54-3.14) 2.23 (1.84-2.70) 1.25 (1.12-1.40) 1.22 (0.98-1.53)
Prior MI (yes vs. no) 0.87 (0.72-1.04) 0.86 (0.61-1.20) 1.05 (0.86-1.28) 0.85 (0.57-1.27)
Prior stroke/TIA (yes vs. no) 1.09 (0.90-1.33) 0.77 (0.54-1.10) 1.11 (0.89-1.39) 0.64 (0.41-0.99)
Heart failure (yes vs. no) 1.45 (1.27-1.66) 1.71 (1.33-2.21) 1.44 (1.23-1.67) 1.54 (1.13-2.09)
PAD (yes vs. no) 1.43 (1.20-1.72) 1.46 (1.02-2.08) 1.51 (1.24-1.85) 1.92 (1.30-2.85)
Neuropathy (yes vs. no) 0.99 (0.86-1.15) 0.80 (0.61-1.04) 1.45 (1.24-1.69) 1.60 (1.21-2.12)
NPDR (yes vs. no) 0.89 (0.70-1.14) 0.64 (0.41-0.99) 0.99 (0.75-1.31) 0.83 (0.52-1.31)
Legend: BMI, body mass index; FPG, fasting blood glucose; PPBG, postprandial blood glucose; HbA1c, glycated hemoglobin; SBP, systolic blood pressure; DBP,
diastolic blood pressure; HR, heart rate; MI, myocardial infarction; TIA, transient ischemic attack; PAD, peripheral arterial disease; NPDR, non-proliferative
diabetic retinopathy.
Table 4 Antidiabetic and antihypertensive therapy by HbA1c and SBP targets at the six-month follow-up
Antidiabetic therapy HbA1c ≤ 6.5% HbA1c > 6.5% to ≤ 7.0% HbA1c >7.0% to ≤ 7.5% p-value at 6 mo*
6 mo ΔBL 6 mo ΔBL 6 mo ΔBL
Metformin (%) 78.1 -0.6 80.9 -0.6 80.3 +0.9 <0.05
Sulfonylureas (%) 15.8 +0.6 19.1 -0.3 21.7 +0.1 <0.0001
Alpha-glucosidase inhibitors (%) 1.0 0.0 1.6 +0.1 0.8 -0.2 <0.05
DPP-4 inhibitors (%) 58.4 -0.6 66.7 +0.3 61.1 -2.2 <0.0001
Glinide (%) 2.5 +0.2 3.7 -0.1 6.6 +0.4 <0.0001
Short-acting insulin (%) 4.6 +0.9 5.3 +1.3 8.7 +2.0 <0.0001
Long-acting insulin (%) 10.3 +1.8 17.4 +2.7 21.7 +4.1 <0.0001
Mixed insulin (%) 0.9 +0.2 2.2 +0.3 3.7 +0.8 <0.0001
≥2 drugs (%) 60.9 +0.3 74.9 +1.5 78.2 +0.8 <0.0001
Antihypertensive therapy SBP ≤ 130 mmHg SBP > 130 to ≤ 135 mmHg SBP > 135 to ≤ 140 mmHg p-value at 6 mo*
6 mo ΔBL 6 mo ΔBL 6 mo ΔBL
ACE inhibitors (%) 50.9 -0.4 53.2 -0.8 54.2 -0.1 0.08
ARBs (%) 28.1 +0.4 28.9 +0.5 27.8 +0.5 0.73
Aliskiren (%) 0.4 -0.1 0.5 0.0 0.3 -0.1 0.74
Betablockers (%) 48.4 +0.6 47.8 +0.6 47.6 +0.7 0.87
Calcium blockers (%) 25.7 +0.6 29.3 +0.8 31.8 +1.0 <0.0001
Diuretics (%) 42.7 +0.4 42.9 +0.2 47.8 +1.3 <0.01
Other (%) 8.9 +0.2 10.5 +0.4 12.8 +0.1 <0.001
≥2 drugs (%) 63.3 +0.6 68.4 +0.3 70.0 +1.5 <0.0001
Legend: HbA1c, glycated hemoglobin; SBP, systolic blood pressure; *p-values compare the HbA1c and SBP groups, respectively.
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showed reductions in mean glucose measurements, with
postprandial glucose dropping to below 10 mmol/l in each
group, overall HbA1c treatment goals remained unmet in
all groups (Figure 3) with 46.3% achieving their pre-
defined treatment target of ≤6.5% (50.2% >6.5 to ≤ 7.0%;
52.2% >7.0 to ≤7.5%). While the lowest mean HbA1c was
achieved with strict treatment, the largest change in
HbA1c from baseline was observed in the loose target
group (p < 0.0001). In addition, when examining BP by
HbA1c target group at follow-up, we observed reductions
from baseline in both SBP and diastolic BP (DBP); how-
ever, there was not a significant difference between the
groups with regard to the observed changes in SBP.
Analyzing the 6-month follow-up data by SBP target
group revealed that patients with strict SBP treatment had
more contacts with general practitioners than the other
groups (p < 0.0001; Table 5). Moreover, patients within
each of the SBP target groups showed reductions in mean
glucose measurements and HbA1c levels from baseline,
with the strict SBP target group displaying the lowest
values (p < 0.0001). Accordingly, the strict group also
showed the least change from baseline HbA1c levels (p <
0.0001). With regard to BP measurements, we observed
reductions from baseline SBP and DBP in all SBP targetTable 5 Patient data at six-month follow-up by HbA1c and SB
HbA1c HbA1c ≤ 6.5%
(n = 2,647)
HbA1c > 6.5% to
(n = 2,790)
GP contacts (number) 5.5 ± 4.8 4.7 ± 3.9
Specialist contacts (number) 2.3 ± 1.9 2.3 ± 2.7
Fasting glucose (mmol/l) 7.0 ± 2.0 7.4 ± 1.9
Postprandial glucose (mmol/l) 8.4 ± 2.5 8.9 ± 2.7
HbA1c (%) 6.8 ± 0.9 7.2 ± 0.9
ΔHbA1c from baseline (%) -0.4 ± 1.2 -0.7 ± 1.2
SBP (mmHg) 135.3 ± 14.1 135.8 ± 13.9
ΔSBP from baseline (mmHg) -4.2 ± 16.7 -5.1 ± 15.6
DBP (mmHg) 80.8 ± 8.8 80.3 ± 8.5
SBP SBP ≤ 130 mmHg
(n = 2,602)
SBP > 130 to ≤ 13
(n = 2,225)
GP contacts (number) 5.5 ± 4.8 4.7 ± 3.7
Specialist contacts (number) 2.3 ± 2.0 2.3 ± 2.4
Fasting glucose (mmol/l) 7.2 ± 2.2 7.4 ± 2.0
Postprandial glucose (mmol/l) 8.8 ± 2.7 8.9 ± 2.3
HbA1c (%) 7.0 ± 1.1 7.2 ± 1.0
ΔHbA1c from baseline (%) -0.5 ± 1.2 -0.7 ± 1.2
SBP (mmHg) 133.4 ± 13.4 135.7 ± 13.3
ΔSBP from baseline (mmHg) -3.0 ± 16.5 -5.2 ± 15.2
DBP (mmHg) 79.9 ± 8.3 80.5 ± 8.2
Legend: HbA1c, glycated hemoglobin; SBP, systolic blood pressure; GP, general pra
mean ± standard deviation.groups. Nevertheless, SBP targets were not reached at six
months in the strict (53.0%) and medium (55.2%) treat-
ment groups by approximately half of the patients only
(Figure 3). In contrast, the SBP target was met in the loose
treatment group in nearly 2/3 (64.8%) of the patients,
which also showed the largest decrease in SBP from base-
line (p < 0.0001).
We also examined the overall distribution of 6-month
outcomes for each of the distinct HbA1c target groups
(Figure 4, upper panel). Interestingly, our analysis con-
firmed that the strictly targeted population as a whole
maintained better glycemic control than the loose pa-
tient group. A similar, but less pronounced, result was
observed when analyzing the different SBP treatment
populations. In contrast, when considering the various
patient populations based on specific comorbidities, we
observed no difference in HbA1c or SBP treatment out-
comes at six months (Figure 4, lower panel).
Discussion
The DIALOGUE registry was designed to study the imple-
mentation and success of individualized treatment targets
for patients with T2DM and hypertension in clinical prac-
tice. We found that patients with strict HbA1c or SBP tar-
gets were younger and displayed shorter disease duration,P target group
≤ 7.0% HbA1c >7.0% to ≤ 7.5%
(n = 1,149)
P-values for the
comparison of 3 groups
5.3 ± 4.4 <0.001
2.3 ± 2.1 <0.05
8.4 ± 2.8 <0.0001
9.8 ± 3.1 <0.0001
7.7 ± 1.2 <0.0001
-0.9 ± 1.5 <0.0001
136.7 ± 14.1 <0.01
-4.7 ± 15.5 0.06
80.4 ± 8.5 0.27
5 mmHg SBP > 135 to ≤ 140 mmHg
(n = 1,729)
P-values for the
comparison of 3 groups
5.2 ± 4.5 <0.0001
2.3 ± 2.6 0.34
7.7 ± 2.3 <0.0001
8.9 ± 3.3 <0.01
7.2 ± 1.1 <0.0001
-0.7 ± 1.3 <0.0001
139.1 ± 14.9 <0.0001
-6.4 ± 16.3 <0.0001
81.4 ± 9.4 <0.0001
ctitioner; DBP, diastolic blood pressure; data are provided as
Figure 3 Target achievement rates at 6 months in each HbA1c and blood pressure target group.
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disease than those with less stringent treatment re-
quirements. Thus, approximately 70% of patients were
assigned to both strict HbA1c and SBP targeting by
physicians. On the other hand, physicians opted for
loose treatment goals in elderly individuals with more
uncontrolled diabetes/BP and comorbidities (i.e., higher
cardiovascular risk). Although individualized therapy
led to substantial reductions in HbA1c and BP after 6-
months of follow-up, treatment goals were often unmet
and no further effort was made to improve the situation
thereafter. Nevertheless, overall HbA1c and SBP levels
remained lowest within the strictly treated patient popula-
tion at the 6-month follow-up.
Individualized treatment targets
Although individualized treatment goals have recently
become a focus in the management of patients with
T2DM [1], the efficacy and safety of such approaches
must be carefully evaluated, and therapeutic criteria
need to be better defined. Therefore, in addition to DIA-
LOGUE, other recent studies have begun to evaluate the
application and outcomes of individualized treatment
guidelines in clinical practice. For example, the Diabetes
in Germany (DIG) study compared various metabolic
syndrome definitions and the consistency of guideline-
oriented treatment across Germany [2-4], whereas, the
DUTY registry evaluated whether treatment guidelines
were effectively incorporated into the management of
patients with diabetes in daily practice [5]. Overall, it
was found that too many patients did not receive con-
sistent therapy for cardiovascular risk factors according
to guidelines, which meant that target values were rarelyreached. Additionally, the prospective DiaRegis registry
was designed to document the therapeutic course and
outcomes of patients with T2DM in which initial antidi-
abetic therapies failed [6]. Among other results, it was
found that that hypoglycemia was more frequent in
T2DM patients with comorbid vascular disease [7].
Moreover, it has been reported that SBP remained un-
controlled in 50% of cases when using individualized
treatment strategies for hypertension [7]. Our findings
from the six-month DIALOGUE follow-up are in agree-
ment with the notion that therapeutic targets are not
currently being met with tailored treatments for diabetes
and hypertension. Indeed, this is consistent with results
from several recent reports that suggested suboptimal
treatment target achievement with respect to both glu-
cose and BP control [8-10]. The failure to achieve pre-
defined treatment has been associated with inertia of
physicians to make effort after an initial failure [11]. On
the other hand multiple concomitant medications as
well as treatment associated side-effects that become ap-
parent after the defining the treatment target frequently
require a reconsideration of these targets in an effort to
balance benefits and risks of treatment [12]. Thus, it is
essential that efforts be made not only to set appropriate
treatment targets, but also to efficiently reach these goals
in clinical practice. In this respect, it is important to de-
termine the factors that play a role in the failure of
current individualized treatment approaches in order to
develop optimal strategies for improvement. Therefore,
our findings from the DIALOGUE registry should con-
tribute to the establishment and maintenance of specific
individualized treatment targets for the management of
patients with T2DM and hypertension.
Figure 4 HbA1c/SBP distribution at 6 months overall and by comorbidity.
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Our findings revealed that patients who underwent strict
treatment for T2DM and hypertension were younger
and less comorbid than those with less stringent therapy
goals. Interestingly, strictly managed patients also made
more contacts with general practitioners and displayed
lower rates of use and doses for various antidiabetic
therapies. In this regard, the increased use of certain an-
tidiabetic and antihypertensive treatments in patientswith loose treatment goals may have contributed to the
greater changes that we observed from baseline values
for both HbA1c and SBP in this group. Indeed, the loose
SBP target group was the only one to meet overall treat-
ment goals in 2/3 of the patients. For reference the
ESH/ESC Guidelines 2013 state that 70% is the target
goal in populations [13]. It is interesting that these pa-
tients with less stringent treatment goals received
heightened therapeutic intervention, as they were older
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lar events. In this regard, there is a particular lack of
data with regard to the use of pharmacologic agents in
older individuals with T2DM, with clinical guidance
largely based on data obtained from younger populations
[14]. Thus, establishing and executing appropriate guide-
lines for individualized pharmacological therapy in older
patients is of critical importance.
With regard to the standards used to assign patients
for targeted therapy, our 6-month analysis of DIA-
LOGUE revealed that a large proportion of patients were
co-stratified into corresponding HbA1c and SBP target
groups (i.e., 70% with strict HbA1c and strict SBP target-
ing). This may not be surprising considering that similar
criteria might be used to establish individualized therapy
for hypertensive or diabetic patients (e.g., comorbidities
and cardiovascular risk) [15]. In this respect, we were
able to determine specific predictors for choosing loose
SBP or HbA1c treatment goals, including unique patient
characteristics (e.g., SBP, FBG, HbA1c levels) as well as
the presence of certain comorbidities (e.g., heart failure,
PAD). Indeed, understanding how such factors are asso-
ciated with specific treatment targets is essential for
evaluating the clinical management of diabetic and
hypertensive patients and determining which patients
will respond well to tailored regimens. Thus, further
study of these patient characteristics can ultimately ensure
that therapeutic goals are met. However, since patients
with both T2DM and hypertension require simultaneous
targeting of BP and glucose levels [16], tailored therapies
for these patients may also need to consider the effects of
combined treatments.
The role and impact of comorbidity
We found that comorbidity was a key factor that influ-
enced the selection of individualized treatment in diabetic
and hypertensive patients. In fact, those with comorbidi-
ties were less likely to receive strict treatment regimens in
our registry. This is in line with the guidance of the
American Diabetes Association on the management of
hyperglycemia [17], suggesting the loosening of glycemic
targets in patients with important comorbidities, estab-
lished vascular disease and limited life expectancy.
Some studies have suggested that comorbidities in
T2DM patients can actually prevent the achievement of
good glycemic control [18-20], whereas others have ar-
gued against this association [21,22]. Nevertheless, Wilke
et al. reported that T2DM patients reaching HbA1c
goals along with additional treatment goals (i.e., for co-
morbidities) showed lower T2DM event rates, whereas
subgroups failing to achieve one or several treatment
goals presented greater risk [23]. That being said, mul-
tiple comorbidities can outbalance the benefit of tight
glycemic control in elderly subjects due to the effects ofhypoglycemia, thereby supporting looser treatment tar-
gets in older individuals [24,25]. In addition to the im-
pact of hypoglycemia on comorbidities, comorbid
conditions may also influence glycemic control. For ex-
ample, the DiaRegis registry reported that hypoglycemia
was more frequent in T2DM patients with vascular dis-
ease [26]. Indeed, it has been suggested that comorbid
illnesses or functional impairments in older diabetic pa-
tients may constitute more important predictors of di-
minished benefit of intensive glucose control than age
alone [27]. In contrast, the impact of comorbidities on
achieving BP targets in high-risk patients is less well
understood [28]. Stricter target BP is now recommended
only in patients with chronic kidney disease or protein-
uria and type 2 diabetes [13]. New studies will further
provide important information on the risks and benefits
of intensive BP treatment targets in patients with exist-
ing comorbidities (e.g., cardiovascular disease, chronic
kidney disease) [29]. So far, in our 6-month analysis of
DIALOGUE, we did not observe differential effects of
specific comorbidities on overall treatment outcomes
(i.e., no difference in six-month HbA1c or SBP outcomes
when analyzing patient populations by specific comor-
bidities). Nevertheless, due to the potential impact that co-
morbidities have on both treatment strategies and patient
outcomes, it was recently suggested that approaches
allowing more complex comorbidity modeling might
enhance the accuracy of individualized therapy [30].
Thus, more research on the epidemiology of complex
comorbidities and how they interact with each other to
change outcomes during tailored treatment of diabetic
and/or hypertensive patients is warranted.
Limitations
This investigation was subject to some limitations. Indeed,
the patients analyzed in the present study were comorbid
for T2DM and hypertension and were often administered
combined therapy regimens which could have confounded
data interpretation. However, since DIALOGUE is an ob-
servational study conducted in real clinical settings with
physician-selected therapy, our results are highly represen-
tative of individualized treatment regimens currently
employed for patients with T2DM and hypertension. In
addition, it has been suggested that registry data can be
less complete when compared to information collected in
randomized clinical trials. However, three strategies were
implemented to assure information quality, including
front-end checks upon data entry, use of a sophisticated
quality control program prior to creation of the analytic
data set, and random site visits. Finally, it is possible that
this 6-month follow-up was not sufficiently long enough
to give an accurate picture of whether individualized BP
and HbA1c treatment goals could be achieved in these
patients.
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In patients with T2DM and hypertension, individualized
glucose and BP targets are selected based on patient
characteristics and overall comorbidity. Thus, those with
low cardiovascular risk have stricter treatment goals. In
this regard, patients with strict HbA1c targets also re-
ceived strict treatment for SBP. Although individualized
treatment led to substantial reductions in HbA1c and
BP after 6-months of follow-up, for the most part, treat-
ment goals were not achieved using various antidiabetic
and antihypertensive therapies. However, as a whole,
strictly treated patients maintained the lowest HbA1c
and BP levels after 6 months of individualized treatment.
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